Johnson & Johnson (NYSE:JNJ) Shares Sold by Hardman Johnston Global Advisors LLC

Posted by Defense World Staff on Aug 12th, 2023

Hardman Johnston Global Advisors LLC lessened its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 149,422 shares of the company’s stock after selling 4,740 shares during the period. Hardman Johnston Global Advisors LLC’s holdings in Johnson & Johnson were worth $23,160,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. DORCHESTER WEALTH MANAGEMENT Co raised its stake in shares of Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after buying an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P raised its position in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares during the period. AMI Investment Management Inc. raised its position in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares during the period. Equitable Holdings Inc. raised its position in shares of Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after purchasing an additional 2,119 shares during the period. Finally, USS Investment Management Ltd raised its position in shares of Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after purchasing an additional 20,528 shares during the period. Institutional investors own 67.57% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $173.85 on Friday. The business’s 50-day moving average price is $164.56 and its two-hundred day moving average price is $161.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04. The company has a market capitalization of $451.83 billion, a P/E ratio of 35.19, a price-to-earnings-growth ratio of 2.90 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.59 EPS. Analysts anticipate that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.74%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Stifel Nicolaus boosted their target price on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Morgan Stanley reaffirmed an “equal weight” rating and set a $187.00 target price on shares of Johnson & Johnson in a research report on Friday, July 21st. Credit Suisse Group upped their price target on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Finally, Raymond James upped their price target on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a research report on Monday, July 24th. Eight investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $171.80.

Get Our Latest Report on Johnson & Johnson

Insider Transactions at Johnson & Johnson

In other news, insider William Hait sold 14,698 shares of the company’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.